HeraMED Limited announced that it has secured a manufacturing agreement with Quasar for its smart ultrasound foetal heart rate monitor, HeraBEAT. The agreement allows HeraMED to immediately scale up production at an improved cost, ahead of commercial rollout of the HeraBEAT device. The Company had previously engaged one of Israel's largest electronics and medical devices manufacturer to build HeraBEAT monitors. While HeraMED plans to maintain the Israeli production line where operable, the new agreement ensures HeraMED can immediately increase device production on a larger scale. Further, the agreement allows for cost effectiveness in the manufacturing process, which has the potential to improve HeraMED's gross margin Quasar holds all required manufacturing certification, including ISO13485, cGMP and has passed multiple FDA audits and inspections. This assists in the initiation phase and scale up of the manufacturing processes. It also ensures HeraMED's products are built to the high standards and leaves HeraMED well placed for its proposed US expansion and FDA approval process.